Nanovibronix (NASDAQ:FEED) Stock Rating Upgraded by Wall Street Zen

Nanovibronix (NASDAQ:FEED) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings began coverage on Nanovibronix in a research report on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nanovibronix currently has a consensus rating of “Sell”.

Nanovibronix Stock Performance

Shares of FEED opened at $2.75 on Friday. The stock has a market cap of $3.00 million, a P/E ratio of -0.07 and a beta of 2.21. Nanovibronix has a 12-month low of $0.99 and a 12-month high of $162.50.

Insider Transactions at Nanovibronix

In other Nanovibronix news, major shareholder Christian Michael Glibert purchased 240,000 shares of the business’s stock in a transaction on Wednesday, January 14th. The stock was purchased at an average price of $2.67 per share, for a total transaction of $640,800.00. Following the completion of the purchase, the insider directly owned 240,000 shares in the company, valued at approximately $640,800. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.20% of the stock is owned by company insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.